Marc Tessier-Lavigne has an estimated net worth of $121 Million. This is based on reported shares across multiple companies, which include REGENERON PHARMACEUTICALS, INC., PFIZER INC, AGIOS PHARMACEUTICALS INC, Denali Therapeutics Inc., Juno Therapeutics, Inc., and GENENTECH INC.

2021 was Marc Tessier-Lavigne's most active year for acquiring shares with 11 total transactions. Marc Tessier-Lavigne's most active month to acquire stocks was the month of December. 2021 was Marc Tessier-Lavigne's most active year for disposing of shares, totalling 42 transactions. Marc Tessier-Lavigne's most active month to dispose stocks was the month of August. 2022 saw Marc Tessier-Lavigne paying a total of $11,894,577.61 for 57,311 shares, this is the most they've acquired in one year. In 2020 Marc Tessier-Lavigne cashed out on 458,558 shares for a total of $24,611,206.99, their largest year based on trade value.